Safety and adverse effects associated with GLP-1 analogues.
about
Liraglutide in the treatment of type 2 diabetes mellitus: clinical utility and patient perspectives.Comparison of safety and tolerability with continuous (exenatide once weekly) or intermittent (exenatide twice daily) GLP-1 receptor agonism in patients with type 2 diabetes.Exenatide: a new promising antidiabetic agent
P2860
Safety and adverse effects associated with GLP-1 analogues.
description
2007 nî lūn-bûn
@nan
2007 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Safety and adverse effects associated with GLP-1 analogues.
@ast
Safety and adverse effects associated with GLP-1 analogues.
@en
Safety and adverse effects associated with GLP-1 analogues.
@nl
type
label
Safety and adverse effects associated with GLP-1 analogues.
@ast
Safety and adverse effects associated with GLP-1 analogues.
@en
Safety and adverse effects associated with GLP-1 analogues.
@nl
prefLabel
Safety and adverse effects associated with GLP-1 analogues.
@ast
Safety and adverse effects associated with GLP-1 analogues.
@en
Safety and adverse effects associated with GLP-1 analogues.
@nl
P2860
P356
P1476
Safety and adverse effects associated with GLP-1 analogues.
@en
P2093
Jeffrey W Stephens
Stephen C Bain
P2860
P304
P356
10.1517/14740338.6.4.417
P407
P577
2007-07-01T00:00:00Z